Literature DB >> 8018506

Lupus nephritis in childhood and adolescence.

J S Cameron1.   

Abstract

Lupus nephritis in childhood usually presents after the age of 10 years, and presentation under 5 years is very rare. More males (F:M ratio 4.5:1) are affected than in adult-onset cases, but the ratio is the same in prepubertal and pubertal children. The incidence of clinically evident renal disease is greater at onset than in adults (82%), the usual presentation being with proteinuria, 50% having a nephrotic syndrome. Half the children show World Health Organisation class IV nephritis in renal biopsies. Neuropsychiatric lupus is present at onset in 30%, may complicate 50% at some point and remains a major problem. Prognosis has improved greatly over the past 30 years, at least in part the result of immunosuppressive treatment. Treatment of the initial phase may be guided by the severity of the renal biopsy appearances, more aggressive treatment including cytotoxic agents, i.v. methylprednisolone and perhaps plasma exchange, although the value of exchange is not established. Controversy persists as to the most effective cytotoxic treatment in the acute phase, both oral and i.v. cyclophosphamide and azathioprine being used in different units. In the chronic maintenance phase it seems established both clinically and histologically that addition of a cytotoxic agent improves outcome, but again the drug and route of administration are contentious. Azathioprine has the advantage of being safe for pregnancy and not gonadotoxic, whilst i.v. cyclophosphamide has been demonstrated to improve results over prednisolone alone in controlled trials and has advantages in non-compliant patients. No trial comparing the two regimes has been carried out, and one is needed. Today children much less commonly go into renal failure, and the main causes of actual death (15% of patients over 10 years) are now infections and extra-renal manifestations of lupus, principally neurological. Morbidity of the disease and the treatment remain a major problem, especially when treatment exacerbates complications of the disease itself, such as infections, osteonecrosis, thrombosis, vascular disease and possibly neoplasia.

Entities:  

Mesh:

Year:  1994        PMID: 8018506     DOI: 10.1007/bf00865490

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  260 in total

1.  STEROID THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON IMMUNOLOGIC CONSIDERATIONS.

Authors:  K LANGE; R ORES; W STRAUSS; M WACHSTEIN
Journal:  Arthritis Rheum       Date:  1965-04

2.  New perspectives on immunointervention in autoimmune diseases.

Authors:  L Adorini; V Barnaba; C Bona; F Celada; A Lanzavecchia; E Sercarz; N Suciu-Foca; H Wekerle
Journal:  Immunol Today       Date:  1990-11

3.  Pulmonary hemorrhage in pediatric patients with systemic lupus erythematosus.

Authors:  R W Miller; J R Salcedo; R J Fink; T M Murphy; D B Magilavy
Journal:  J Pediatr       Date:  1986-04       Impact factor: 4.406

4.  Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities.

Authors:  K Nagasawa; Y Ishii; T Mayumi; Y Tada; A Ueda; Y Yamauchi; T Kusaba; Y Niho
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

5.  Lupus nephritis: clinical and pathological correlation.

Authors:  B Leaker; K F Fairley; J Dowling; P Kincaid-Smith
Journal:  Q J Med       Date:  1987-02

6.  Bacterial endocarditis complicating systemic lupus erythematosus.

Authors:  T J Lehman; S T Palmeri; C Hastings; J H Klippel; P H Plotz
Journal:  J Rheumatol       Date:  1983-08       Impact factor: 4.666

7.  Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients.

Authors:  R S Glidden; E C Mantzouranis; Y Borel
Journal:  Clin Immunol Immunopathol       Date:  1983-11

8.  Acute renal failure as the initial manifestation of systemic lupus erythematosus in children.

Authors:  K Phadke; H Trachtman; A Nicastri; C K Chen; A Tejani
Journal:  J Pediatr       Date:  1984-07       Impact factor: 4.406

9.  Atrial fibrillation following methylprednisolone pulse therapy.

Authors:  N Ueda; T Yoshikawa; M Chihara; S Kawaguchi; Y Niinomi; T Yasaki
Journal:  Pediatr Nephrol       Date:  1988-01       Impact factor: 3.714

10.  Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis.

Authors:  T M Schmiedeke; F W Stöckl; R Weber; Y Sugisaki; S R Batsford; A Vogt
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  33 in total

Review 1.  The use of immunosuppressive and cytotoxic drugs in non-malignant disease.

Authors:  P A Brogan; M J Dillon
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

Review 2.  New developments in the treatment of systemic lupus erythematosus.

Authors:  Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2011-04-26       Impact factor: 3.714

3.  End-stage renal disease as the presenting manifestation of renal systemic lupus erythematosus.

Authors:  Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2006-09-15       Impact factor: 3.714

4.  Full-house nephropathy in a patient with negative serology for lupus.

Authors:  Esra Baskin; Pinar Isik Agras; Nurcan Menekşe; Handan Ozdemir; Nurcan Cengiz
Journal:  Rheumatol Int       Date:  2006-09-14       Impact factor: 2.631

5.  Lupus nephritis in Egyptian children: a 16-year experience.

Authors:  Atef Elmougy; Amr Sarhan; Ayman Hammad; Ahmed El-Refaey; Mohammed Zedan; Riham Eid; Wafaa Laimon; Wafaa Limon; Ashraf Abd Elrahman; Fatma Elhussieni; Enas El-Sherbeny; Ashraf Bakr
Journal:  J Nephrol       Date:  2014-12-10       Impact factor: 3.902

Review 6.  [Systemic lupus erythematosus in children and adolescents].

Authors:  S Sallmann; B Fiebig; C M Hedrich; G Heubner; M Gahr
Journal:  Z Rheumatol       Date:  2006-11       Impact factor: 1.372

7.  Childhood lupus nephritis: 12 years experience from North India.

Authors:  Surjit Singh; Ranjana Minz; Ritambhra Nada; Kusum Joshi
Journal:  Rheumatol Int       Date:  2006-05       Impact factor: 2.631

8.  Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population.

Authors:  Linda T Hiraki; Candace H Feldman; Jun Liu; Graciela S Alarcón; Michael A Fischer; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2012-08

Review 9.  Membranous lupus nephritis in Chinese children--a case series and review of the literature.

Authors:  Sik-Nin Wong; Winnie Kwai-Yu Chan; Joannie Hui; Stella Chim; Tsz-Leung Lee; Kwok-Piu Lee; Lettie Chuk-Kwan Leung; Niko Kei-Chiu Tse; So-Fun Yuen
Journal:  Pediatr Nephrol       Date:  2009-07-22       Impact factor: 3.714

10.  Mesenteric thrombosis causing short bowel syndrome in nephrotic syndrome.

Authors:  Tim Ulinski; Vincent Guigonis; Valérie Baudet-Bonneville; Frédéric Auber; Karine Garcette; Albert Bensman
Journal:  Pediatr Nephrol       Date:  2003-10-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.